Back

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - Discussion.

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Controversies in antithrombotic treatment for primary and secondary prevention Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2019

5 More presentations in this session

Presentation thumbnail
Aspirin is out for primary prevention of cardiovascular disease - PRO.
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
Aspirin is out for primary prevention of cardiovascular disease - CON.
Professor C. Patrono (Rome, IT)
Slides Video
Presentation thumbnail
Aspirin is out for primary prevention of cardiovascular disease - Discussion.
Video
Presentation thumbnail
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.
Doctor J. Eikelboom (Hamilton, CA)
Slides Video
Presentation thumbnail
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - CON.
Doctor T. Cuisset (Marseille, FR)
Slides Video

Access the full session

Session thumbnail
Controversies in antithrombotic treatment for primary and secondary prevention

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Medical treatment works! Contemporary implementation into clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources